Literature DB >> 2014207

Quantitative structure-activity relationships (QSARs) of pyrimidine nucleosides as HIV-1 antiviral agents.

M Mahmoudian1.   

Abstract

The structural requirements for the antiviral activity of pyrimidine nucleosides against HIV-1 virus was evaluated with the Hansch SAR analysis. Antiviral activity is best related to the hydrophobicity and steric (L and B3) properties of the substituent at the C5 of pyrimidine ring. Further, the antiviral activity is related to B4 of the substituent at position 3' of the sugar ring with a positive slope. The activity of both uracil and cytosine derivatives can be related to their structure by the same equations, which indicates that the SARs are similar in these two groups of congeners. These results suggest that compounds with a small substituent at the 5 position of the pyrimidine ring and a flat substituent at the 3' position of the sugar ring will be the most active compounds against HIV-1 virus.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2014207     DOI: 10.1023/a:1015822105022

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  5 in total

Review 1.  Spectrum of antiviral activity and mechanism of action of zidovudine. An overview.

Authors:  P A Furman; D W Barry
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

2.  Synthesis and antiviral activity of various 3'-azido analogues of pyrimidine deoxyribonucleosides against human immunodeficiency virus (HIV-1, HTLV-III/LAV).

Authors:  T S Lin; J Y Guo; R F Schinazi; C K Chu; J N Xiang; W H Prusoff
Journal:  J Med Chem       Date:  1988-02       Impact factor: 7.446

3.  Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.

Authors:  C K Chu; R F Schinazi; M K Ahn; G V Ullas; Z P Gu
Journal:  J Med Chem       Date:  1989-03       Impact factor: 7.446

4.  Results of continued monitoring of participants in the placebo-controlled trial of zidovudine for serious human immunodeficiency virus infection.

Authors:  D D Richman; J Andrews
Journal:  Am J Med       Date:  1988-08-29       Impact factor: 4.965

5.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

  5 in total
  1 in total

1.  Solubility enhancement of nucleosides and structurally related compounds by complex formation.

Authors:  A X Chen; S W Zito; R A Nash
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.